How big is Biogen, Inc.?

As of Jun 18, Biogen, Inc. has a market capitalization of $21.56 billion, with net sales of $9.40 billion and a net profit of $1.48 billion over the latest four quarters. Shareholder's funds total $16.72 billion, and total assets are $28.05 billion.

Market Cap: As of Jun 18, Biogen, Inc. has a market capitalization of 21,556.69 million, classifying it as a Large Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Biogen reported net sales of 9,402.30 million and a net profit of 1,479.40 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company's shareholder's funds amounted to 16,716.00 million, while total assets were reported at 28,049.30 million.

What does Biogen, Inc. do?

Biogen, Inc. is a biopharmaceutical company specializing in therapies for neurological, rare, and autoimmune diseases, with a market cap of approximately $21.56 billion. As of March 2025, it reported net sales of $2.34 billion and a net profit of $240 million.

Overview: <BR>Biogen, Inc. is a biopharmaceutical company that focuses on discovering, developing, manufacturing, and delivering therapies for serious neurological, rare, and autoimmune diseases, operating within the Pharmaceuticals & Biotechnology industry and classified as a Large Cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 2,336 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 240 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 21,556.69 Million (Large Cap)<BR><BR>Key Metrics: <BR>P/E: 13.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.22 <BR>Return on Equity: 10.03% <BR>Price to Book: 1.27<BR><BR>Contact Details: <BR>Address: 225 Binney St, CAMBRIDGE MA: 02142-1031 <BR>Tel: 1 781 4642000 <BR>Website: https://www.biogen.com/

Should I buy, sell or hold Biogen, Inc.?

Who are in the management team of Biogen, Inc.?

As of March 2022, Biogen, Inc.'s management team includes Dr. Stelios Papadopoulos (Independent Chairman), Mr. Michel Vounatsos (CEO), and several Independent Directors: Dr. Alexander Denner, Ms. Caroline Dorsa, Mr. William Hawkins, Ms. Nancy Leaming, and Mr. Jesus Mantas. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Biogen, Inc. includes the following individuals:<BR><BR>- Dr. Stelios Papadopoulos, who serves as the Independent Chairman of the Board.<BR>- Mr. Michel Vounatsos, who is the Chief Executive Officer and a Director.<BR>- Dr. Alexander Denner, who is an Independent Director.<BR>- Ms. Caroline Dorsa, who is also an Independent Director.<BR>- Mr. William Hawkins, serving as an Independent Director.<BR>- Ms. Nancy Leaming, who is an Independent Director.<BR>- Mr. Jesus Mantas, who is an Independent Director.<BR><BR>This team is responsible for guiding the strategic direction and operations of the company.

Is Biogen, Inc. overvalued or undervalued?

As of October 17, 2025, Biogen, Inc. is considered fairly valued with a P/E ratio of 13 and an EV to EBITDA of 9.17, but has significantly underperformed the S&P 500 with a 1-year return of -24.56% and a 5-year return of -48.93%.

As of 17 October 2025, the valuation grade for Biogen, Inc. has moved from very attractive to attractive, indicating a shift in perception. The company appears to be fairly valued based on its current metrics, with a P/E ratio of 13, an EV to EBITDA of 9.17, and a PEG ratio of 0.61. In comparison, peers such as the industry average P/E of approximately 13.57 and an EV to EBITDA of 8.89 suggest that Biogen is slightly below the average in terms of valuation ratios.<BR><BR>Despite the attractive valuation, Biogen has underperformed significantly against the S&P 500, with a 1-year return of -24.56% compared to the index's 14.08%. This trend continues over longer periods, with a 5-year return of -48.93% versus the S&P's 91.29%, highlighting the challenges the company faces in the market.

Is Biogen, Inc. technically bullish or bearish?

As of October 31, 2025, Biogen, Inc. shows a bullish trend with mixed signals, as the weekly MACD and moving averages are bullish, but the monthly MACD is only mildly bullish and Bollinger Bands indicate bearishness, while its performance has lagged behind the S&P 500.

As of 31 October 2025, the technical trend for Biogen, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, and the daily moving averages also indicate a bullish stance. However, the monthly MACD is only mildly bullish, and Bollinger Bands show a bearish signal on the monthly timeframe. The KST is bullish on the weekly and mildly bullish on the monthly, while Dow Theory indicates a mildly bullish trend on the weekly but no trend on the monthly.<BR><BR>Despite the current bullish trend, Biogen's performance has been significantly underwhelming compared to the S&P 500, with a -14.07% return over the past year versus the S&P 500's 19.89%. Overall, the technical stance is bullish but with caution due to mixed signals in longer timeframes.